ENZO BIOCHEM INC Form 8-K June 07, 2016		
UNITED STATES		
SECURITIES AND EXCH	HANGE COMMISSION	
Washington, DC 20549		
FORM 8-K		
CURRENT REPORT		
Pursuant to Section 13 or	15(d) of the	
Securities Exchange Act of	f 1934	
Date of report (Date of earli	iest event reported): June 7, 2016	
Enzo Biochem, Inc.		
(Exact Name of Registrant a	as Specified in Its Charter)	
New York		
(State or Other Jurisdiction	of Incorporation)	
001-09974	13-2866202	

001-09974 13-2866202 (Commission File Number) (IRS Employer Identification No.)

527 Madison Avenue

New York, New York 10022 (Address of Principal Executive Offices) (Zip Code)
(212) 583-0100
(Registrant's Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other events

On June 7, 2016 Enzo Biochem, Inc. (the "Company") issued a press release titled "Enzo Biochem Announces New York State Approval of New Women's Test Based on Proprietary Technology" for its AmpiProbe CandidiasisTM assay.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of Enzo Biochem, Inc., dated June 7, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: June 7, 2016 By:/s/ Barry W. Weiner Barry W. Weiner President